Open Access

H2Mab‑19, an anti‑human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts

  • Authors:
    • Junko Takei
    • Mika Kato Kaneko
    • Tomokazu Ohishi
    • Manabu Kawada
    • Hiroyuki Harada
    • Yukinari Kato
  • View Affiliations

  • Published online on: May 18, 2020     https://doi.org/10.3892/etm.2020.8765
  • Pages: 846-853
  • Copyright : © Takei et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human epidermal growth factor receptor 2 (HER2) is reported to be overexpressed in breast cancers and is associated with poor clinical outcome. Trastuzumab is a humanized anti‑HER2 antibody that offers significant survival benefits to patients with HER2‑overexpressing breast cancer. In this study, a novel anti‑HER2 monoclonal antibody (mAb), H2Mab‑19 (IgG2b, kappa) was developed. Antibody‑dependent cellular cytotoxicity (ADCC), complement‑dependent cytotoxicity (CDC), and antitumor activity of H2Mab‑19 were investigated using both breast cancer and oral cancer cell lines. H2Mab‑19 demonstrated cytotoxicity in BT‑474 (a human breast cancer cell line) and HSC‑2 or SAS (human oral cancer cell lines). H2Mab‑19 also possessed both ADCC and CDC activity against BT‑474, HSC‑2, and SAS cell lines. In comparison to control mouse IgG, H2Mab‑19 significantly reduced tumor development in BT‑474, HSC‑2, and SAS xenografts. Collectively, these results suggest that treatment with H2Mab‑19 may be a useful therapy for patients with HER2‑expressing breast and oral cancers.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Takei, J., Kaneko, M.K., Ohishi, T., Kawada, M., Harada, H., & Kato, Y. (2020). H2Mab‑19, an anti‑human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts. Experimental and Therapeutic Medicine, 20, 846-853. https://doi.org/10.3892/etm.2020.8765
MLA
Takei, J., Kaneko, M. K., Ohishi, T., Kawada, M., Harada, H., Kato, Y."H2Mab‑19, an anti‑human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts". Experimental and Therapeutic Medicine 20.2 (2020): 846-853.
Chicago
Takei, J., Kaneko, M. K., Ohishi, T., Kawada, M., Harada, H., Kato, Y."H2Mab‑19, an anti‑human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts". Experimental and Therapeutic Medicine 20, no. 2 (2020): 846-853. https://doi.org/10.3892/etm.2020.8765